These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 39204314)

  • 1. The Role of Inhaled Chitosan-Based Nanoparticles in Lung Cancer Therapy.
    Silva AC; Costa MP; Zacaron TM; Ferreira KCB; Braz WR; Fabri RL; Frézard FJG; Pittella F; Tavares GD
    Pharmaceutics; 2024 Jul; 16(8):. PubMed ID: 39204314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
    Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
    Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancements in Chitosan-Based Nanoparticles for Pulmonary Drug Delivery.
    Zacaron TM; Silva MLSE; Costa MP; Silva DME; Silva AC; Apolônio ACM; Fabri RL; Pittella F; Rocha HVA; Tavares GD
    Polymers (Basel); 2023 Sep; 15(18):. PubMed ID: 37765701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.
    Mangal S; Gao W; Li T; Zhou QT
    Acta Pharmacol Sin; 2017 Jun; 38(6):782-797. PubMed ID: 28504252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Present Situation and Future Progress of Inhaled Lung Cancer Therapy: Necessity of Inhaled Formulations with Drug Delivery Functions.
    Okuda T; Okamoto H
    Chem Pharm Bull (Tokyo); 2020; 68(7):589-602. PubMed ID: 32611996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-Based Nanocarriers for Targeted Gene Delivery in Lung Cancer Therapy: Exploring a Novel Therapeutic Paradigm.
    Beigi A; Naghib SM; Matini A; Tajabadi M; Mozafari MR
    Curr Gene Ther; 2024 May; ():. PubMed ID: 38778601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Chitosan and its Derivatives in Nanocarrier Based Pulmonary Drug Delivery Systems.
    Dua K; Bebawy M; Awasthi R; Tekade RK; Tekade M; Gupta G; De Jesus Andreoli Pinto T; Hansbro PM
    Pharm Nanotechnol; 2017; 5(4):243-249. PubMed ID: 28786352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface-engineered smart nanocarrier-based inhalation formulations for targeted lung cancer chemotherapy: a review of current practices.
    Yu XY; Jin X; Shou ZX
    Drug Deliv; 2021 Dec; 28(1):1995-2010. PubMed ID: 34569401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment.
    Choukaife H; Seyam S; Alallam B; Doolaanea AA; Alfatama M
    Int J Nanomedicine; 2022; 17():3933-3966. PubMed ID: 36105620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nano-based targeted drug delivery for lung cancer: therapeutic avenues and challenges.
    Ezhilarasan D; Lakshmi T; Mallineni SK
    Nanomedicine (Lond); 2022 Oct; 17(24):1855-1869. PubMed ID: 35311343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled Micro/Nanoparticulate Anticancer Drug Formulations: An Emerging Targeted Drug Delivery Strategy for Lung Cancers.
    Islam N; Richard D
    Curr Cancer Drug Targets; 2019; 19(3):162-178. PubMed ID: 29793407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy.
    Jin Z; Gao Q; Wu K; Ouyang J; Guo W; Liang XJ
    Adv Drug Deliv Rev; 2023 Nov; 202():115111. PubMed ID: 37820982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted drug nanocrystals for pulmonary delivery: a potential strategy for lung cancer therapy.
    Kumar M; Jha A; Dr M; Mishra B
    Expert Opin Drug Deliv; 2020 Oct; 17(10):1459-1472. PubMed ID: 32684002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update.
    Abdulbaqi IM; Assi RA; Yaghmur A; Darwis Y; Mohtar N; Parumasivam T; Saqallah FG; Wahab HA
    Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dry Powder form of Polymeric Nanoparticles for Pulmonary Drug Delivery.
    Shiehzadeh F; Tafaghodi M
    Curr Pharm Des; 2016; 22(17):2549-60. PubMed ID: 26818872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.
    Youngren-Ortiz SR; Gandhi NS; España-Serrano L; Chougule MB
    Kona; 2016 Feb; 33():63-85. PubMed ID: 27081214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonviral pulmonary delivery of siRNA.
    Merkel OM; Kissel T
    Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations.
    Bielski E; Zhong Q; Mirza H; Brown M; Molla A; Carvajal T; da Rocha SRP
    Int J Pharm; 2017 Jul; 527(1-2):171-183. PubMed ID: 28549971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled lipid nanocarriers for pulmonary delivery of glucocorticoids: Previous strategies, recent advances and key factors description.
    Altube MJ; Perez N; Romero EL; Morilla MJ; Higa LH; Perez AP
    Int J Pharm; 2023 Jul; 642():123146. PubMed ID: 37330156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.